Copernicus Group IRB — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$4,699	2
2020	Research	$83,600	75
2019	Research	$26,243	31

Breakdown

Who paid Research payments · program years 2019–2021

Provepharm Inc. $44,560 16 payments
CSL Behring $30,888 38 payments
Abbott Laboratories $19,503 29 payments
Ipsen Innovation $14,412 18 payments
Djo, LLC $4,879 6 payments
Vifor Fresenius Medical Care Renal Pharma Ltd. $300 1 payment

Studies the money was for Research payments · program years 2019–2021

Pvp-Ic1901 $44,560 16 payments
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease $30,888 38 payments
LIFE-BTK Randomized Controlled Trial $17,814 26 payments
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis $14,412 18 payments
Ps-607 $4,879 6 payments
LIFE-BTK Randomized Controlled Trial $1,189 1 payment
EValuating Anatomic vErsus TaRgeted Lead Placement for BurstDR TherapY During the Trial (DELIVERY) $500 2 payments
An Study to Investigate the Safety and Efficacy of PA21 (Velphoro) and Calcium Acetate (Phoslyra) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia $300 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.